Onglyza® and Kombiglyze® XR Heart Failure and Cancer Lawsuits
Part of a family of prescription drugs known as incretin mimetics, Onglyza® (saxagliptin) and Kombiglyze® XR (saxagliptin and metformin HCl) are used to treat Type 2 diabetes. But new data suggests that taking Onglyza or Kombiglyze XR may increase the risk of pancreatic cancer, thyroid cancer, and heart failure, a fatal condition in which the heart can’t pump enough blood to meet the body’s needs.
If you or a loved one were diagnosed with pancreatic cancer, thyroid cancer, or suffered severe or fatal heart problems after taking Onglyza or Kombiglyze XR, the drug injury lawyers at Ferrer, Poirot & Wansbrough want to help. We have more than three decades of experience helping injury victims, and we’re committed to reforming the pharmaceutical industry through litigation. Let us help with your Onglyza injury claim today—call (800) 210-8503 or complete our free online form.
Onglyza® and Kombiglyze® Heart Failure Risks
In October 2013, a New England Journal of Medicine study revealed an increased risk of hospitalization for heart failure after taking saxagliptin. This prompted the U.S. Food and Drug Administration (FDA) to launch an investigation into the link between Onglyza/Kombiglyze XR and heart failure.
In April 2015, an FDA advisory committee concluded that patients who take Onglyza or Kombiglyze XR face an increased risk of heart failure. According to a study cited by FDA officials, patients taking saxagliptin showed a 27 percent increase in the rate of first-time hospitalization due to heart failure.
As a result, the FDA recommended that AstraZeneca, manufacturer of Onglyza and Kombiglyze XR update the drug’s labeling to warn patients of an increased risk of heart failure.
Onglyza®, Kombiglyze® XR, and Pancreatic Cancer
A 2013 study uncovered a potential link between incretin mimetic diabetes drugs, such as Onglyza and Kombiglyze XR, and pre-cancerous changes of the pancreas. The FDA is continuing to evaluate these claims and is urging patients and health care professionals to report pancreatic side effects.
Incretin Mimetics and Thyroid Cancer
Victoza®, an incretin mimetic diabetes drug that shares similarities with Onglyza and Kombiglyze XR, has been linked to an increased risk of thyroid cancer in animal studies. Although the risk to humans is still being evaluated, Victoza drug packaging carries a black box warning—the strongest warning that can be issued by the FDA—advising doctors and patients of the cancer risk.
Time Limits to File an Onglyza® or Kombiglyze® Lawsuit
Your time to file a lawsuit is limited if you or someone you love suffered heart failure or were diagnosed with cancer after taking Onglyza or Kombiglyze XR. At Ferrer, Poirot & Wansbrough, our drug injury lawyers are ready to help protect your rights to compensation. Contact our 24/7 team to get started with your claim now—just dial (800) 210-8503 or fill out our free online form.
Onglyza® and Kombiglyze XR® are registered trademarks of AstraZeneca PLC, and are used here only to identify the products in question. Victoza® is a registered trademark of Novo Nordisk A/S and is used here only to identify the product in question.
This law firm is not associated with, sponsored by, or affiliated with AstraZeneca PLC; Investor’s Business Daily; The New England Journal of Medicine; Novo Nordisk A/S; or the U.S. Food and Drug Administration.